Achieve Life Sciences, Inc.
ACHV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.16 | 0.04 | 0.25 | 0.08 |
| FCF Yield | -26.37% | -29.99% | -144.68% | -46.63% |
| EV / EBITDA | -2.94 | -3.10 | -0.43 | -0.61 |
| Quality | ||||
| ROIC | -121.86% | -178.30% | -99.43% | -76.20% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.75 | 0.82 | 0.89 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -21.51% | 34.75% | -27.47% | -118.35% |
| Safety | ||||
| Net Debt / EBITDA | 0.07 | -0.04 | 0.21 | 1.31 |
| Interest Coverage | -17.92 | -9.55 | -22.81 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.09 | 0.00 |
| Cash Conversion Cycle | -3,108.08 | -989.34 | -6,423.07 | -1,227.86 |